Disclosed is the use of glucosylglycerol for the manufacture of a pharmaceutical for protecting a keratoconjunctiva or suppressing a keratoconjunctival disorder. The protection of the keratoconjunctiva or the suppression of the a keratoconjunctival disorder may include a protection of the keratoconjunctiva against an endogenous disease of Sjogren&rsquos syndrome, Stevens-Johnson syndrome, or dry eye syndrome (dry eye) or an exogenous disease due to post-surgery, a drug, an injury, or the wearing of a contact lens or the suppression of the keratoconjunctival disorder due to said diseases.